<DOC>
	<DOC>NCT01282762</DOC>
	<brief_summary>The purpose of this study is to determine the durability of seroprotection of HEPLISAV™ and Engerix-B® and the number of injections of each vaccine needed to maintain seroprotection in a cohort of chronic kidney disease (CKD) patients over time.</brief_summary>
	<brief_title>Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease</brief_title>
	<detailed_description>An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV™ compared with Engerix-B® in Adults with Chronic Kidney Disease who Have Previously Received At Least One Hepatitis B Vaccine Series</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A subject must meet all of the following inclusion criteria to participate in the study: enrolled and completed HEPLISAV or EngerixB treatment in: DV2HBV17 or DV2HBV18 and had antiHBsAg ≥ 10 mIU/mL prior to or during DV2HBV18 previously received a complete primary hepatitis B vaccine series in DV2HBV17 or prior to enrollment in DV2HBV18 be otherwise clinically stable in the opinion of the investigator be able and willing to provide informed consent A subject who meets any ONE of the following exclusion criteria is not permitted to participate in the study: previously enrolled in DV2HBV18 and never obtained antiHBsAg ≥ 10 mIU/mL received hepatitis B vaccine offstudy after enrolling in DV2HBV17 or DV2HBV18 has known history of autoimmune disease is unwilling or unable to comply with all the requirements of the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prevention of Hepatitis B infection.</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Hepatitis B vaccination</keyword>
	<keyword>Hepatitis B virus (HBV)</keyword>
</DOC>